US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
ドイツ
TG
Buzzi Spa (UCM) 銘柄情報

Buzzi Spa (UCM)

47.81

0.00

( 0.00% )

更新日時： 16:11:35

Buzzi Spa (UCM) 銘柄情報

個人投資家向けのプロ仕様のツール。

プレミアム

通貨

47.81

( - )

買値

47.98

売値

48.00

出来高

0.00

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

時価総額

前日終値

47.81

始値

-

時刻

最終取引時間

-

財務取引量

-

VWAP

-

平均取引量 (3 か月)

521,433 €

発行済株式数

178,762,666

配当利回り

0.7 (1.47%)

PER

9.08

1 株当たり利益 (EPS)

5.09

歳入

4.53B

純利益

921.31M

Buzzi S.p.A., together with its subsidiaries, manufactures, distributes, and sells cement, ready-mix concrete, and natural aggregates. It has operations primarily in Italy, United States of America, Germany, Luxembourg, Netherlands, United Arab Emirates, Poland, Czech Republic and Slovakia, Brazil, ... Buzzi S.p.A., together with its subsidiaries, manufactures, distributes, and sells cement, ready-mix concrete, and natural aggregates. It has operations primarily in Italy, United States of America, Germany, Luxembourg, Netherlands, United Arab Emirates, Poland, Czech Republic and Slovakia, Brazil, Russia, Algeria, Slovenia, and Mexico. The company was formerly known as Buzzi Unicem S.p.A. and changed its name to Buzzi S.p.A. in May 2023. The company was founded in 1872 and is headquartered in Casale Monferrato, Italy. 詳細を表示

セクター

Materials

業界

Construction Materials

ウェブサイト

www.buzzi.com

本社

Casale Monferrato, Italy

設立

1872

Buzzi Spa is listed in the Materials sector of the Tradegate (DE) with ticker UCM. The last closing price for Buzzi was 47.81 €. Over the last year, Buzzi shares have traded in a share price range of 0.00 € to 0.00 €.

Buzzi currently has 178,762,666 shares in issue. The market capitalisation of Buzzi is 8.55 € billion. Buzzi has a price to earnings ratio (PE ratio) of 9.08.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

UCM - Frequently Asked Questions (FAQ)

What is the current Buzzi Spa share price?

The current share price of Buzzi Spa is 47.81 €

How many Buzzi Spa shares are in issue?

Buzzi Spa has 178,762,666 shares in issue

What is the market cap of Buzzi Spa?

The market capitalisation of Buzzi Spa is EUR 8.55B

What is the 1 year trading range for Buzzi Spa share price?

Buzzi Spa has traded in the range of 0.00 € to 0.00 € during the past year

What is the PE ratio of Buzzi Spa?

The price to earnings ratio of Buzzi Spa is 9.08

What is the cash to sales ratio of Buzzi Spa?

The cash to sales ratio of Buzzi Spa is 1.82

What is the registered address of Buzzi Spa?

The registered address for Buzzi Spa is Via Luigi Buzzi, 6, Casale Monferrato, Alessandria, 15033

What is the Buzzi Spa website address?

The website address for Buzzi Spa is www.buzzi.com

Which industry sector does Buzzi Spa operate in?

Buzzi Spa operates in the Construction Materials sector

US Market News

US Market News 12分前

Unilever Scales Digital Twins Across Global Manufacturing Network with AccentureJune 16, 2026 2:59 AM
Business WireUnilever (LON: ULVR) is partnering with Accenture (NYSE: ACN) to scale the use of AI-enabled digital twins across its global manufacturing network

CelestialSage6

CelestialSage6 14分前

You can't refute it. Yes, I understand your level well.

biotechinvestor1

biotechinvestor1 20分前

Total nonsense! I have no interest in educating you.

Nemesis18

Nemesis18 21分前

She'll probably move to somewhere without any extradition treaty once the plug is finally pulled on this 'cancer vaccine' scam.?

price_and_volume

price_and_volume 23分前

Gonna have to bump the A/S then...
He said recently that they are looking at another acquisition...and he will dilute with shares to get it. Agreed - I posted the same, "where's the finance coming from for acquisitions?"...

Supposed 400MM shares going to $GTVH (believe it when

StockItOut

StockItOut 24分前

WKSP Weekly chart: https://schrts.co/IIIuZpgy

CelestialSage6

CelestialSage6 25分前

I understand that Halozyme has not signed any exclusive agreements regarding treatments or indications related to Dupixent, so why is Sanofi collaborating with Alteogen?

Also, Halozyme's mdase patent is being invalidated due to Merck. Alteogen's technology is more advanced than Halozy

Wolf-man jack

Wolf-man jack 27分前

WQLF SAYS: Have Mercy WQLF ahoooooo

Q: Why hasn't CV SCIENCES been accepted in the CMS Medicare Pilot Program?

Ai Generated:

C V Sciences has not been "accepted" into the CMS Medicare Pilot Program because the pilot is a provider-led incentive, not a

price_and_volume

price_and_volume 28分前

What reasonable expectation is there of PPS responding?
whether management can successfully execute on the vision they have laid out. Nobody cares about "the company" or "the management" or "their vision" or your two-bit-MBA-tutorials-in-a-post.

Enough of all that garbage.

mrwrn2010

mrwrn2010 31分前

Disagree. The outcome of OxyContin litigation was unknown 9 months to a year ago. You can guess at a variety of outcomes, sure, but it’s not certain. Same thing with human trials - we don’t have positive trial results for anything in the pipeline until we have them. What passes in vitro may not pass

PEACHMAN

PEACHMAN 33分前

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177680761

IFUS STRONG

price_and_volume

price_and_volume 34分前

I get that, but that's not what I asked.

I'm not bullying you or accusing you of pumping.

You repeatedly point out what you consider to be nefarious shenanigans, so I asked: PPS hasn't effectively changed in THREE YEARS , other than a few short days 1 year ago this wee

Homework.Investwell

Homework.Investwell 40分前

2017 Northwest Biotherapeutics, Inc.
4800 Montgomery Lane, Suite 800

Suite 800 is empty....🤔

Linda lives in Missouri now but headquarters could be moved anywhere...or will they need it?

I think we're going to find out by the end of the sum

Mdk1

Why this paper is highly interesting for Lightwave Logic (GROK)
This is a top-scored paper that strongly validates Lightwave Logic’s Perkinamine™ chromophore series 3 as a leading electro-optic material for next-generation datacenter optics.

Key Reasons Why It Matters:

janice shell

janice shell 49分前

Now that's a real head-scratcher! But shorts have to be smart, so I'd say torso and head.

gitreal

gitreal 52分前

Anyone with half a Brian can see this company is being crazy shorted!

Which half? Torso and head?

HyGro

NWBO could file an FDA application anytime but they haven't and have shown no intent to do so. Instead they are just burning more shareholder cash and if approved, will lose money on every dose because NICE will hammer the reimbursement down below Advent's costs. NWBO will lose money and collaps

US Market News

US Market News 57分前

TotalEnergies SE: Disclosure of Transactions in Own SharesJune 16, 2026 2:00 AM
Business Wire Regulatory News In accordance with the authorizations given by the shareholders’ general meeting on May 29, 2026, to trade on its shares and pursuant to applicable law on share

HyGro

Sorry, not enough. NWBO won't make any profit selling in the UK. NICE hates personalized oncology treatments and won't pay enough for NWBO to make a profit.
That's what counts. And NWBO will go under or just become Advent Contract Manufacturer. They have no cash or credit to fund any sub

biotechinvestor1

biotechinvestor1 1時間前

Don’t start spazzing again, Alteogen circus clown. The Sanofi news is old.
Once Merck settles/licenses from Halozyme, Sanofi and all others will follow.
Your Alteogen stole IP from Halozyme and will pay a price for it. You can count on it.
The companies who have signed with Alte

Steady_T

Steady_T 1時間前

Your theory will be put to the test after UK approval. I give it 6 months as a guess.

HyGro

HyGro 1時間前

What's true is NWBO won't file with the FDA for approval in the U.S. Hasn't done it for years when it could have done it. They know FDA won't accept their P3 trial. How many years are you going to wait to find out???

HyGro

HyGro 1時間前

What's True is NWBO won't file with the FDA for approval in the U.S. Hasn't done it for years when it could have done it. They know FDA won't accept their P3 trial. How long are you going to wait to find out???

Mdk1

Mdk1 1時間前

Google Scholar alert - new article: "A Comparison of Plasmonic Modulator Structures in the O- and C-Band for the 400G/Lane IM/DD Era"
>>> " In ALL cases, the same electro-optic organic material, Lightwave Logic’s PerkinamineTM
chromophore series 3, was used " !
https://ieeexplor

CelestialSage6

CelestialSage6 1時間前

Stop talking nonsense. Sanofi is conducting clinical trials using Alteogen's technology; what are your thoughts on this? Did you sense a crisis for Halozyme?

Plaza Centers NV

Hospitals Paris Fixed In...

US Treasury 3 Year Note ...

Domestic bond 1.125% 12a...

Les Motocycles Ardoin St...

Stand.chart 26u

OMX Baltic Media GI

2% 03nov2027 2% 03nov2027

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。